Jefferies analyst Maury Raycroft downgraded Reata Pharmaceuticals (RETA) to Hold from Buy with a price target of $172.50, up from $104, after Biogen (BIIB) agreed to acquire Reata for $172.50 per share in cash.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RETA:
- Reata Pharmaceuticals downgraded to Neutral from Buy at Guggenheim
- Reata Pharmaceuticals downgraded to Neutral from Overweight at Cantor Fitzgerald
- Reata Pharmaceuticals downgraded to Hold from Buy at Stifel
- Biogen Snaps Up Reata Pharma In $7.3B Deal
- Biogen to acquire Reata Pharmaceuticals for $172.50 per share in cash